{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:24:57Z","timestamp":1791591897440,"version":"4.3.4"},"reference-count":101,"publisher":"Elsevier","isbn-type":[{"value":"9780323983921","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.acr.2022.01.008","type":"book-chapter","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T07:42:47Z","timestamp":1646034167000},"page":"167-199","source":"Crossref","is-referenced-by-count":7,"title":["Novel insights into molecular and immune subtypes of biliary tract cancers"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.acr.2022.01.008_bb0010","doi-asserted-by":"crossref","first-page":"22087","DOI":"10.1038\/s41598-020-77939-6","article-title":"Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer","volume":"10","author":"Abdel-Wahab","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.acr.2022.01.008_bb0015","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"The Lancet Oncology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0020","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"The Lancet Oncology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0025","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ccell.2021.03.012","article-title":"Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations","volume":"39","author":"Affo","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.acr.2022.01.008_bb0030","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s12072-019-09954-3","article-title":"Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach","volume":"13","author":"Ahn","year":"2019","journal-title":"Hepatology International"},{"key":"10.1016\/bs.acr.2022.01.008_bb0035","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.hpb.2018.07.021","article-title":"Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma","volume":"21","author":"Akita","year":"2019","journal-title":"HPB: The Official Journal of the International Hepato Pancreato Biliary Association"},{"issue":"4","key":"10.1016\/bs.acr.2022.01.008_bb0040","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.12.005","article-title":"Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors","volume":"142","author":"Andersen","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0045","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0050","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: Cholangiocarcinoma: Current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0055","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0060","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s12094-015-1436-2","article-title":"Biliary tract cancers: SEOM clinical guidelines","volume":"17","author":"Benavides","year":"2015","journal-title":"Clinical & Translational Oncology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0065","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0070","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/13543784.2021.1896703","article-title":"Rare cancer, rare alteration: The case of NTRK fusions in biliary tract cancers","volume":"30","author":"Boileve","year":"2021","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/bs.acr.2022.01.008_bb0075","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precision Oncology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004135","article-title":"Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma","volume":"10","author":"Borad","year":"2014","journal-title":"PLoS Genetics"},{"key":"10.1016\/bs.acr.2022.01.008_bb0085","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/bs.acr.2022.01.008_bb0090","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"Bridgewater","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA repair in cancer: Beyond PARP inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.acr.2022.01.008_bb0100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/bs.acr.2022.01.008_bb0105","article-title":"Intrahepatic cholangiocarcinoma: Genomic heterogeneity between eastern and Western patients. JCO precis","volume":"4","author":"Cao","year":"2020","journal-title":"Oncologia"},{"key":"10.1016\/bs.acr.2022.01.008_bb0110","article-title":"The immunogenomic landscape of resected intrahepatic cholangiocarcinoma","author":"Carapeto","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2019.07.022","article-title":"Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker","volume":"120","author":"Chae","year":"2019","journal-title":"European Journal of Cancer"},{"issue":"57\u201370","key":"10.1016\/bs.acr.2022.01.008_bb0120","article-title":"Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma","volume":"32","author":"Chaisaingmongkol","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.acr.2022.01.008_bb0125","article-title":"OncoKB: A precision oncology Knowledge Base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precision Oncology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0130","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers","volume":"45","author":"Chan-On","year":"2013","journal-title":"Nature Genetics"},{"key":"10.1016\/bs.acr.2022.01.008_bb0135","article-title":"Multiomic analysis reveals comprehensive tumor heterogeneity and distinct immune subtypes in multifocal intrahepatic cholangiocarcinoma","author":"Chen","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.acr.2022.01.008_bb0140","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1158\/0008-5472.CAN-08-0742","article-title":"Focal gains of VEGFA and molecular classification of hepatocellular carcinoma","volume":"68","author":"Chiang","year":"2008","journal-title":"Cancer Research"},{"key":"10.1016\/bs.acr.2022.01.008_bb0145","first-page":"957","article-title":"Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma","volume":"21","author":"Chuaysri","year":"2009","journal-title":"Oncology Reports"},{"key":"10.1016\/bs.acr.2022.01.008_bb0150","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/s41587-021-00857-z","article-title":"Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology","volume":"39","author":"Deveson","year":"2021","journal-title":"Nature Biotechnology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0155","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"The Lancet Oncology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0160","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.acr.2022.01.008_bb0165","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: Integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"The Lancet Oncology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0170","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"18","author":"Farshidfar","year":"2017","journal-title":"Cell Reports"},{"key":"10.1016\/bs.acr.2022.01.008_bb0175","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.31110","article-title":"Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals therapeutic opportunities","volume":"72","author":"Goeppert","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0180","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41416-018-0199-2","article-title":"Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma","volume":"120","author":"Goeppert","year":"2019","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.acr.2022.01.008_bb0185","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/hep.30493","article-title":"Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma","volume":"69","author":"Goeppert","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0190","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion\u2013positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.acr.2022.01.008_bb0195","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion\u2013positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.acr.2022.01.008_bb0200","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Human Pathology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0205","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","article-title":"BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition","volume":"11","author":"Hofmann","year":"2021","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.acr.2022.01.008_bb0210","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1158\/0008-5472.CAN-09-1089","article-title":"Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma","volume":"69","author":"Hoshida","year":"2009","journal-title":"Cancer Research"},{"key":"10.1016\/bs.acr.2022.01.008_bb0215","first-page":"604","article-title":"Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma","volume":"49","author":"Isa","year":"2002","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0220","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000511919","article-title":"ERBB2 pathway in biliary tract carcinoma: Clinical implications of a targetable pathway","volume":"44","author":"Jacobi","year":"2021","journal-title":"Oncology Research and Treatment"},{"key":"10.1016\/bs.acr.2022.01.008_bb0225","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet","author":"Javle","year":"2021","journal-title":"Gastroenterolog\u00eda y Hepatolog\u00eda"},{"key":"10.1016\/bs.acr.2022.01.008_bb0230","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nature Genetics"},{"key":"10.1016\/bs.acr.2022.01.008_bb0235","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/hep.31092","article-title":"Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma","volume":"72","author":"Job","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0240","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.acr.2022.01.008_bb0245","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0016-5085(03)00278-6","article-title":"Epigenetic and genetic alterations in duodenal carcinomas are distinct from biliary and ampullary carcinomas","volume":"124","author":"Kim","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0250","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/bjc.2016.311","article-title":"PARP inhibitors for BRCA1\/2-mutated and sporadic ovarian cancer: Current practice and future directions","volume":"115","author":"Konecny","year":"2016","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.acr.2022.01.008_bb0255","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1200\/GO.20.00030","article-title":"Lack of targetable FGFR2 fusions in endemic fluke-associated cholangiocarcinoma","volume":"6","author":"Kongpetch","year":"2020","journal-title":"JCO Global Oncology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0260","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"The Lancet Oncology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0265","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/bs.acr.2022.01.008_bb0270","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.acr.2022.01.008_bb0275","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/annonc\/mdt384","article-title":"PARP inhibitors for BRCA1\/2 mutation-associated and BRCA-like malignancies","volume":"25","author":"Lee","year":"2014","journal-title":"Annals of Oncology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0280","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/gutjnl-2018-316039","article-title":"Genomic ERBB2\/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: A whole-exome sequencing analysis","volume":"68","author":"Li","year":"2019","journal-title":"Gut"},{"key":"10.1016\/bs.acr.2022.01.008_bb0285","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/ng.3030","article-title":"Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway","volume":"46","author":"Li","year":"2014","journal-title":"Nature Genetics"},{"key":"10.1016\/bs.acr.2022.01.008_bb0290","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cell.2017.01.014","article-title":"Applications of immunogenomics to cancer","volume":"168","author":"Liu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/bs.acr.2022.01.008_bb0295","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic Cholangiocarcinomas: Potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.acr.2022.01.008_bb0300","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-20-2771","article-title":"FDA approval summary: Entrectinib for the treatment of NTRK gene fusion solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.acr.2022.01.008_bb0305","article-title":"A novel stroma, tumor, immune microenvironment-based classification of intrahepatic cholangiocarcinoma","author":"Martin-Serrano","year":"2021"},{"key":"10.1016\/bs.acr.2022.01.008_bb0310","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2020.05.014","article-title":"Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer","volume":"73","author":"McNamara","year":"2020","journal-title":"Journal of Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0315","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0168-8278(01)00106-4","article-title":"Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma","volume":"35","author":"Momoi","year":"2001","journal-title":"Journal of Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0320","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"Journal of Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0325","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: Is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/bs.acr.2022.01.008_bb0330","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nature Genetics"},{"key":"10.1016\/bs.acr.2022.01.008_bb0335","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-020-1063-5","article-title":"Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies","volume":"26","author":"Nakamura","year":"2020","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.acr.2022.01.008_bb0340","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/hep.29764","article-title":"Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma","volume":"68","author":"Nepal","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0345","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jhep.2020.11.033","article-title":"Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes","volume":"74","author":"Nepal","year":"2021","journal-title":"Journal of Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0350","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/hep.25890","article-title":"Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma","volume":"56","author":"Oishi","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0355","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/ng.2273","article-title":"Exome sequencing of liver fluke-associated cholangiocarcinoma","volume":"44","author":"Ong","year":"2012","journal-title":"Nature Genetics"},{"key":"10.1016\/bs.acr.2022.01.008_bb0360","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1038\/s41467-020-17880-4","article-title":"Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate","volume":"11","author":"Pandey","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/bs.acr.2022.01.008_bb0365","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"International Journal of Cancer"},{"key":"10.1016\/bs.acr.2022.01.008_bb0370","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5114\/ceh.2019.85166","article-title":"Epidemiology of gallbladder cancer","volume":"5","author":"Rawla","year":"2019","journal-title":"Journal of Clinical and Experimental Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0375","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/bs.acr.2022.01.008_bb0380","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, diagnosis, and management of cholangiocarcinoma","volume":"145","author":"Rizvi","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0385","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1517\/13543784.2015.1096344","article-title":"Entrectinib: A potent new TRK, ROS1, and ALK inhibitor","volume":"24","author":"Rolfo","year":"2015","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/bs.acr.2022.01.008_bb0390","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"The Oncologist"},{"issue":"15","key":"10.1016\/bs.acr.2022.01.008_bb0395","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/jco.2015.33.15_suppl.4009","article-title":"(2015). Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations","volume":"33","author":"Ross","year":"2015","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0400","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/2159-8290.CD-15-1442","article-title":"Isocitrate dehydrogenase mutations confer Dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma","volume":"6","author":"Saha","year":"2016","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.acr.2022.01.008_bb0405","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature13441","article-title":"Mutant IDH inhibits HNF-4\u03b1 to block hepatocyte differentiation and promote biliary cancer","volume":"513","author":"Saha","year":"2014","journal-title":"Nature"},{"key":"10.1016\/bs.acr.2022.01.008_bb0410","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1053\/j.gastro.2013.01.001","article-title":"Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes","volume":"144","author":"Sia","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0415","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1038\/ncomms7087","article-title":"Massive parallel sequencing uncovers actionable FGFR2\u2013PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma","volume":"6","author":"Sia","year":"2015","journal-title":"Nature Communications"},{"key":"10.1016\/bs.acr.2022.01.008_bb0420","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/j.gastro.2016.11.048","article-title":"Liver cancer cell of origin, molecular class, and effects on patient prognosis","volume":"152","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0425","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to Pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.acr.2022.01.008_bb0430","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.acr.2022.01.008_bb0435","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000682","article-title":"Molecular profile of BRCA-mutated biliary tract cancers","volume":"5","author":"Spizzo","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/bs.acr.2022.01.008_bb0440","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Science Translational Medicine"},{"key":"10.1016\/bs.acr.2022.01.008_bb0445","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13087","article-title":"Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma","volume":"49","author":"Tamma","year":"2019","journal-title":"European Journal of Clinical Investigation"},{"key":"10.1016\/bs.acr.2022.01.008_bb0450","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.18632\/oncotarget.27224","article-title":"Germline mutations in cancer-predisposition genes in patients with biliary tract cancer","volume":"10","author":"Terashima","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acr.2022.01.008_bb0455","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.24351","article-title":"Risk factors for cholangiocarcinoma","volume":"54","author":"Tyson","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0460","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Annals of Oncology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0465","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.acr.2022.01.008_bb0470","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.acr.2022.01.008_bb0475","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","article-title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","volume":"68","author":"Wardell","year":"2018","journal-title":"Journal of Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0480","doi-asserted-by":"crossref","first-page":"652","DOI":"10.21037\/jgo.2018.08.18","article-title":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","volume":"10","author":"Weinberg","year":"2019","journal-title":"Journal of Gastrointestinal Oncology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0485","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.acr.2022.01.008_bb0490","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccell.2015.12.012","article-title":"Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma","volume":"29","author":"Yachida","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.acr.2022.01.008_bb0495","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s005350070036","article-title":"Microsatellite instability in gallbladder carcinoma: Two independent genetic pathways of gallbladder carcinogenesis","volume":"35","author":"Yoshida","year":"2000","journal-title":"Journal of Gastroenterology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0500","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jhep.2020.05.039","article-title":"Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma","volume":"73","author":"Zhang","year":"2020","journal-title":"Journal of Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0505","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jhep.2021.06.023","article-title":"Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer","volume":"75","author":"Zhang","year":"2021","journal-title":"Journal of Hepatology"},{"key":"10.1016\/bs.acr.2022.01.008_bb0510","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nature Communications"}],"container-title":["Advances in Cancer Research","Hepatobiliary Cancers: Translational Advances and Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X22000215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X22000215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:07:32Z","timestamp":1762229252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065230X22000215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323983921"],"references-count":101,"URL":"https:\/\/doi.org\/10.1016\/bs.acr.2022.01.008","relation":{},"ISSN":["0065-230X"],"issn-type":[{"value":"0065-230X","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}